| Primary |
| Breast Cancer |
32.5% |
| Breast Cancer Metastatic |
27.3% |
| Non-small Cell Lung Cancer |
14.1% |
| Hodgkin's Disease |
4.0% |
| Product Used For Unknown Indication |
3.4% |
| Lung Neoplasm Malignant |
2.5% |
| Drug Use For Unknown Indication |
2.2% |
| Prostate Cancer |
2.2% |
| Neoplasm Malignant |
1.6% |
| Adenocarcinoma |
1.4% |
| Her-2 Positive Breast Cancer |
1.4% |
| Malignant Lymphoid Neoplasm |
1.4% |
| Hiv Infection |
1.1% |
| Acute Myeloid Leukaemia |
0.7% |
| Cervix Carcinoma Recurrent |
0.7% |
| Lung Adenocarcinoma |
0.7% |
| Non-small Cell Lung Cancer Stage Iv |
0.7% |
| Vulval Cancer Metastatic |
0.7% |
| B Precursor Type Acute Leukaemia |
0.5% |
| Breast Cancer Stage Iii |
0.5% |
|
| Neutropenia |
41.5% |
| Febrile Neutropenia |
12.3% |
| Death |
5.8% |
| Neutropenic Infection |
5.8% |
| Mucosal Inflammation |
5.3% |
| Vomiting |
4.7% |
| Ventricular Dysfunction |
3.5% |
| Skin Toxicity |
2.9% |
| Sepsis |
2.3% |
| Asthenia |
1.8% |
| Drug Toxicity |
1.8% |
| Pneumonia |
1.8% |
| Pulmonary Embolism |
1.8% |
| Pyrexia |
1.8% |
| Cardiac Failure |
1.2% |
| Constipation |
1.2% |
| Drug Exposure During Pregnancy |
1.2% |
| Ejection Fraction Decreased |
1.2% |
| Haemoptysis |
1.2% |
| Ileus Paralytic |
1.2% |
|
| Secondary |
| Product Used For Unknown Indication |
33.0% |
| Breast Cancer Metastatic |
18.4% |
| Breast Cancer |
13.2% |
| Non-small Cell Lung Cancer |
10.5% |
| Diffuse Large B-cell Lymphoma |
3.1% |
| Lung Neoplasm Malignant |
2.6% |
| Sarcoma Metastatic |
2.6% |
| Acute Myeloid Leukaemia |
2.0% |
| Hodgkin's Disease |
1.5% |
| Drug Use For Unknown Indication |
1.4% |
| Her-2 Positive Breast Cancer |
1.4% |
| Hiv Infection |
1.4% |
| Neoplasm Malignant |
1.3% |
| Prophylaxis |
1.3% |
| Ovarian Cancer |
1.2% |
| Hepatosplenic T-cell Lymphoma |
1.1% |
| Rhabdomyosarcoma |
1.1% |
| Synovial Sarcoma |
1.1% |
| Non-hodgkin's Lymphoma |
1.0% |
| Adverse Event |
0.8% |
|
| Neutropenia |
28.0% |
| Febrile Neutropenia |
8.8% |
| Vulvovaginal Dryness |
7.3% |
| Bone Marrow Failure |
6.7% |
| Vomiting |
5.2% |
| White Blood Cell Count Decreased |
5.2% |
| Pulmonary Embolism |
4.7% |
| Neoplasm Progression |
3.6% |
| Disease Progression |
3.1% |
| Malignant Neoplasm Progression |
3.1% |
| Pyrexia |
3.1% |
| Sepsis |
3.1% |
| Deep Vein Thrombosis |
2.6% |
| General Physical Health Deterioration |
2.6% |
| Thrombocytopenia |
2.6% |
| Drug Ineffective |
2.1% |
| Mucosal Inflammation |
2.1% |
| Neutropenic Sepsis |
2.1% |
| Neutrophil Count Decreased |
2.1% |
| Pneumocystis Jiroveci Pneumonia |
2.1% |
|
| Concomitant |
| Breast Cancer Metastatic |
19.0% |
| Non-small Cell Lung Cancer |
12.1% |
| Breast Cancer |
11.5% |
| Cancer Pain |
6.9% |
| Analgesic Therapy |
4.6% |
| Breast Cancer Recurrent |
4.6% |
| Constipation |
4.6% |
| Prophylaxis |
4.6% |
| Anaemia |
4.0% |
| Metastases To Bone |
4.0% |
| Lung Neoplasm Malignant |
3.4% |
| Hypertension |
2.9% |
| Metastases To Liver |
2.9% |
| Cough |
2.3% |
| Hodgkin's Disease |
2.3% |
| Insomnia |
2.3% |
| Nausea |
2.3% |
| White Blood Cell Count Decreased |
2.3% |
| Crohn's Disease |
1.7% |
| Large Cell Lung Cancer Stage Ii |
1.7% |
|
| Vomiting |
11.6% |
| Breast Cancer |
9.3% |
| Death |
9.3% |
| Acute Myeloid Leukaemia |
7.0% |
| Tooth Fracture |
7.0% |
| White Blood Cell Count Decreased |
7.0% |
| Hepatic Failure |
4.7% |
| Monoplegia |
4.7% |
| Paraesthesia |
4.7% |
| Pneumonia Primary Atypical |
4.7% |
| Subclavian Vein Thrombosis |
4.7% |
| Tumour Lysis Syndrome |
4.7% |
| Ulcerative Keratitis |
4.7% |
| Ascites |
2.3% |
| Cardiac Failure |
2.3% |
| Cardiomegaly |
2.3% |
| Dermatomyositis |
2.3% |
| Fatigue |
2.3% |
| Hypersensitivity Vasculitis |
2.3% |
| Ileus |
2.3% |
|
